Get the Latest from Taussig Experts
on the Front Lines of Medicine
Invest in the future of medicine.
Envision the limitless possibilities.
Join Sam Palmisano of IBM, Daniel Vasella, MD of Novartis, David Brennan of AstraZeneca, Fred Hassan of Schering-Plough, Richard Clark of Merck, and many other distinguished industry leaders at the 7th Annual Medical Innovation Summit. Take advantage of our exciting lineup of speakers, panel discussions, live surgeries and clinical presentations to learn about the latest trends in medical innovation and what they mean to you.
The Summit provides an unrivaled perspective on the newest medical technologies and the financial drivers behind those innovations. It is dedicated to providing singular insights, networking opportunities and actionable take away for all participants.
Summit highlights include:
- Candid exchanges with the investors and executives who are shaping the future of medical innovation.
- Discussions with world leaders responsible for the change in health care technology
- Detailed insights into the newest innovations in cancer therapeutics, diagnostics and disease management systems
- First-hand analysis on new directions for supporting innovation
- Top 10 Medical Innovations for 2010
- Live, interactive surgery
Register Now!
Daniel Vasella, M.D., is Chairman and Chief Executive Officer (CEO) of Novartis AG.
He was appointed Chairman in April 1999, having served as CEO and executive member of the Board of Directors since the merger that created
Novartis in 1996.
Sam Palmisano is Chairman of the Board,
President and Chief Executive Officer of the IBM Corporation. Mr. Palmisano was appointed to this position on January 6, 2003. Previously,
he served as President and Chief Operating Officer.
David Brennan was appointed Chief Executive Officer of
AstraZeneca effective 1 January 2006 and is now based at the global headquarters in London. From 2001 until his appointment to CEO, David was
President and Chief Executive Officer of AstraZeneca LP, the Company’s North American subsidiary for the U.S. and Canada. He was appointed
Executive Board Director of AstraZeneca in 2005.
Fred Hassan is chairman of the board and chief executive
officer of Schering-Plough Corporation. Prior to joining Schering-Plough in April 2003 and assuming his current position, Hassan was chairman and
chief executive officer of Pharmacia Corporation. He joined the former Pharmacia & Upjohn in May 1997 as chief executive officer and was elected
to the Board of Directors.
Richard T. Clark is the Chairman, President and Chief Executive Officer
of Merck & Co., Inc., a global research-driven pharmaceutical company that discovers, develops, manufactures and markets innovative medicines and
vaccines. Mr. Clark has been President and CEO of Merck since May 2005, and chairman of the board since April 2007.
Margaret A. Hamburg, M.D., was confirmed on May 18, 2009 by
a unanimous Senate voice vote to become the 21st Food and Drug Commissioner. The second woman to be nominated for that demanding position, Dr.
Hamburg is exceptionally qualified for her new job by her training and experience as a medical doctor, scientist and public health executive.
Maria Bartiromo is the anchor of CNBC's "Closing Bell with
Maria Bartiromo," and host and managing editor of the nationally syndicated business, financial and economic news program, "Wall Street Journal
Report with Maria Bartiromo," which was recently rated the most watched financial news program in America. It appears on over 200 stations weekly
and provides the clarity, depth and insight of The Wall Street Journal in a television magazine format. She contributes to NBC's Today Show, Today
In L.A., Today in Chicago and CNBC Asia's daily broadcasts.
